XTX Topco Ltd Buys New Shares in Athira Pharma, Inc. (NASDAQ:ATHA)

XTX Topco Ltd bought a new stake in Athira Pharma, Inc. (NASDAQ:ATHA) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 22,695 shares of the company’s stock, valued at approximately $60,000. XTX Topco Ltd owned 0.06% of Athira Pharma as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jacobs Levy Equity Management Inc. lifted its holdings in Athira Pharma by 84.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 497,475 shares of the company’s stock valued at $1,363,000 after buying an additional 227,278 shares during the period. Perceptive Advisors LLC lifted its holdings in Athira Pharma by 12.6% in the fourth quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock valued at $13,129,000 after buying an additional 605,686 shares during the period. Acadian Asset Management LLC lifted its holdings in Athira Pharma by 281.5% in the first quarter. Acadian Asset Management LLC now owns 549,938 shares of the company’s stock valued at $1,505,000 after buying an additional 405,793 shares during the period. Mirador Capital Partners LP acquired a new position in Athira Pharma in the first quarter valued at $57,000. Finally, Forefront Analytics LLC lifted its holdings in Athira Pharma by 43.0% in the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock valued at $72,000 after buying an additional 8,955 shares during the period. Institutional investors and hedge funds own 57.12% of the company’s stock.

Athira Pharma Price Performance

NASDAQ:ATHA opened at $0.44 on Thursday. The firm has a 50-day moving average of $2.09 and a 200-day moving average of $2.36. The company has a market cap of $16.93 million, a PE ratio of -0.14 and a beta of 2.90. Athira Pharma, Inc. has a one year low of $0.41 and a one year high of $4.30.

Athira Pharma (NASDAQ:ATHA) last posted its earnings results on Thursday, August 1st. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.05. On average, equities research analysts expect that Athira Pharma, Inc. will post -2.57 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ATHA shares. Rodman & Renshaw lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th. Mizuho lowered shares of Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $5.00 to $0.50 in a report on Thursday, September 19th. JMP Securities lowered shares of Athira Pharma from an “outperform” rating to a “market perform” rating in a report on Wednesday, September 4th. Finally, BTIG Research lowered shares of Athira Pharma from a “buy” rating to a “neutral” rating in a report on Wednesday, September 4th.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.